AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab
AGC Biologics April 29, 2020 at 3:49 PM
The drug, Leronlimab, owned by CytoDyn, containing a special molecule manufactured by AGC Biologics, is showing favorable results in the treatment of severely affected COVID-19 patients. AGC Biologics stands ready to ramp up manufacturing to meet demand once this drug is FDA approved.
AGC Biologics Announces Leadership Updates Amid Groundbreaking of New Yokohama Site
December 22, 2024 at 6:00 PM